

Honghui Zhou

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11410197/honghui-zhou-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

95
papers

3,311
citations

31
h-index

56
g-index

97
ext. papers

3,698
ext. citations

4
avg, IF

5.18
L-index

#	Paper	IF	Citations
95	Improving categorical endpoint longitudinal exposure-response modeling through the joint modeling with a related endpoint. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021 , 1	2.7	0
94	Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis. <i>Clinical and Translational Science</i> , 2021 ,	4.9	1
93	Utilization of physiologically-based pharmacokinetic model to assess disease-mediated therapeutic protein-disease-drug interaction in immune-mediated inflammatory diseases. <i>Clinical and Translational Science</i> , 2021 ,	4.9	1
92	Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab. <i>Clinical and Translational Science</i> , 2020 , 13, 1217-1226	4.9	4
91	Applying Beta Distribution in Analyzing Bounded Outcome Score Data. <i>AAPS Journal</i> , 2020 , 22, 61	3.7	4
90	Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 1573-1584	2.9	7
89	Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 889-902	2.9	9
88	Application of Beta-Distribution and Combined Uniform and Binomial Methods in Longitudinal Modeling of Bounded Outcome Score Data. <i>AAPS Journal</i> , 2020 , 22, 95	3.7	2
87	Translational Model-Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ-54175446, a P2X7 Receptor Antagonist. <i>Clinical and Translational Science</i> , 2020 , 13, 309-317	1.9	0
86	Facilitating Longitudinal Exposure-Response Modeling of a Composite Endpoint Using the Joint Modeling of Sparsely and Frequently Collected Subcomponents. <i>AAPS Journal</i> , 2020 , 22, 79	3.7	
85	Application of Trial Simulation in the Design of a Prospective Study for Concentration-QTc Analysis in Support of a Thorough QT Study Waiver. <i>AAPS Journal</i> , 2020 , 22, 101	3.7	0
84	What We Can Learn from Current Inflammatory Bowel Disease (IBD) Biological Therapy Dose Regimen and Others. <i>Current Pharmacology Reports</i> , 2019 , 5, 115-130	5.5	0
83	Antibody-Based Biotherapeutics in Inflammatory Diseases 2019 , 557-617		
82	Pharmacokinetics-Based Dosing for Therapeutic Monoclonal Antibodies in Inflammatory Bowel Disease 2019 , 243-253		
81	Application of Pharmacometrics and Systems Pharmacology to Current and Emerging Biologics in Inflammatory Bowel Diseases 2019 , 209-242		
80	Pharmacokinetics-Based Dosing Strategies for Therapeutic Proteins in Inflammatory Bowel Disease 2019 , 255-284		
79	Quantitative Pharmacology Approach to Select Optimal Dose and Study the Important Factors in Determining Disposition of Therapeutic Monoclonal Antibody in Pediatric Subjects Some Considerations 2019 , 285-314		1

78	Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins for Plaque Psoriasis [Guselkumab 2019 , 337-361		
77	Vedolizumab [Case Example of Using Quantitative Pharmacology in Developing Therapeutic Biologics in Inflammatory Bowel Disease 2019 , 363-387		
76	Case Examples of Using Quantitative Pharmacology in Developing Therapeutic Proteins in Systemic Lupus Erythematosus [Belimumab 2019 , 389-400		
75	Mechanism and Physiologically Based PK/PD Model in Assisting Translation from Preclinical to Clinical: Understanding PK/PD of Therapeutic Proteins at Site-of-Action 2019 , 43-64		
74	Application of Minimal Anticipated Biological Effect Level (MABEL) in Human Starting Dose Selection for Immunomodulatory Protein Therapeutics [Principles and Case Studies 2019 , 65-91		
73	Utility of Joint Population Exposure-Response Modeling Approach to Assess Multiple Continuous and Categorical Endpoints in Immunology Drug Development 2019 , 125-147		
72	Translational Considerations in Developing Bispecific Antibodies: What Can We Learn from Quantitative Pharmacology? 2019 , 187-208		
71	Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 590-604	2.9	11
70	Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 864-876	2.9	13
69	Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF Monoclonal Antibody. <i>AAPS Journal</i> , 2018 , 20, 63	3.7	10
68	Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1 Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 613-627	2.9	28
67	Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 939-951	2.9	3
66	A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018 , 45, 523-535	2.7	11
65	Exposure-Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1501-1515	2.9	1
64	Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018 , 45, 803-816	2.7	7
63	Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018 , 45, 679-691	2.7	7
62	Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017 , 44, 425-436	2.7	8
61	Landmark and longitudinal exposure-response analyses in drug development. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017 , 44, 503-507	2.7	13

60	Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017 , 44, 437-448	2.7	15
59	Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 35-46	1.5	76
58	Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6. <i>AAPS Journal</i> , 2016 , 18, 767-76	3.7	17
57	Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model. <i>Pharmaceutical Research</i> , 2016 , 33, 1040-1045	4.5	5
56	Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1323-1331	5.5	7
55	Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach. <i>European Journal of Pharmaceutical Sciences</i> , 2016 , 94, 46-58	5.1	12
54	Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector. <i>Clinical Therapeutics</i> , 2015 , 37, 427-38	3.5	7
53	Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. <i>Journal of Clinical Pharmacology</i> , 2015 , 55 Suppl 3, S60-74	2.9	31
52	Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 1386-94	2.9	50
51	Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015 , 117, 219-25	3.1	10
50	Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014 , 41, 335-49	2.7	16
49	Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2014 , 41, 239-50	2.7	12
48	Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. <i>Gastroenterology</i> , 2014 , 147, 1296-1307.e5	13.3	233
47	Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial. <i>Clinical Drug Investigation</i> , 2013 , 33, 795-800	3.2	16
46	Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies. <i>Clinical Drug Investigation</i> , 2013 , 33, 291-301	3.2	11
45	Rational development and utilization of antibody-based therapeutic proteins in pediatrics. <i>Pharmacology & Therapeutics</i> , 2013 , 137, 225-47	13.9	45
44	Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2753-62	4.5	55
43	Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update. <i>Annals of the New York Academy of Sciences</i> , 2012 , 1263, 1-12	6.5	27

42	Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. <i>Clinical Therapeutics</i> , 2012 , 34, 77-90	3.5	63
41	Characterizing the impact of renal impairment on the clinical pharmacology of biologics. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 54S-62S	2.9	91
40	Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. <i>Nature Biotechnology</i> , 2011 , 29, 615-24	44.5	114
39	Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 639-48	2.9	25
38	Monoclonal antibodies: interspecies scaling with minimal preclinical information. <i>Therapeutic Delivery</i> , 2011 , 2, 359-68	3.8	9
37	Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 270-81	3.8	76
36	Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. <i>Annals of the New York Academy of Sciences</i> , 2011 , 1222, 30-9	6.5	40
35	Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. <i>Clinical Therapeutics</i> , 2011 , 33, 946-64	3.5	198
34	Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011 , 38, 237-60	2.7	27
33	Bounded outcome score modeling: application to treating psoriasis with ustekinumab. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011 , 38, 497-517	2.7	27
32	Confirmatory analysis for phase III population pharmacokinetics. <i>Pharmaceutical Statistics</i> , 2011 , 10, 14-26		31
31	Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 276-84	2.9	75
30	Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 792-802	2.9	24
29	Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α (TNF- α). <i>MAbs</i> , 2010 , 2, 428-39	6.6	168
28	Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 257-67	2.9	44
27	A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010 , 37, 309-21	2.7	22
26	Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. <i>Drug Discovery Today</i> , 2009 , 14, 891-8	8.8	34
25	Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. <i>European Journal of Clinical Pharmacology</i> , 2009 , 65, 1211-28	2.8	229

24	Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 162-75	2.9	127
23	Interspecies scaling of therapeutic monoclonal antibodies: initial look. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 1382-402	2.9	106
22	In Vivo Evaluation of Oral Dosage Form Performance 2009 , 365-378		2
21	Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 1056-70	2.9	70
20	An improved approach for confirmatory phase III population pharmacokinetic analysis. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 812-22	2.9	32
19	Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 681-95	2.9	89
18	Water-Insoluble Drugs and Their Pharmacokinetic Behaviors 2008 , 91-100		2
17	Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 1104-18	2.9	79
16	Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 553-65	2.9	69
15	Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 383-96	2.9	142
14	Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 1268-89	2.9	28
13	Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 246-56	2.9	61
12	Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 490-7	2.9	81
11	Evidence of effectiveness: how much can we extrapolate from existing studies?. <i>AAPS Journal</i> , 2005 , 7, E467-74	3.7	19
10	Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. <i>Journal of Clinical Pharmacology</i> , 2004 , 44, 1235-43	2.9	42
9	"Cocktail" approaches and strategies in drug development: valuable tool or flawed science?. <i>Journal of Clinical Pharmacology</i> , 2004 , 44, 120-34	2.9	67
8	Absence of a pharmacokinetic interaction between etanercept and warfarin. <i>Journal of Clinical Pharmacology</i> , 2004 , 44, 543-50	2.9	33
7	Absence of a clinically relevant interaction between etanercept and digoxin. <i>Journal of Clinical Pharmacology</i> , 2004 , 44, 1244-51	2.9	27

6	Pharmacokinetic strategies in deciphering atypical drug absorption profiles. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 211-27	2.9	100
5	Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 543-52	3.8	10
4	Nateglinide, a New Mealtime Glucose Regulator. <i>Clinical Drug Investigation</i> , 2000 , 19, 465-471	3.2	10
3	Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). <i>Journal of Clinical Pharmacology</i> , 1999 , 39, 911-9	2.9	31
2	Impact of Diseases, Comorbidity, and Target Physiology on ADME, PK, and PK/PD of Therapeutic Biologics1-221		
1	Statistical Considerations in Assessing Drug-Drug Interactions for Therapeutic Biologics1		